Astellas Pharma Inc. (ALPMF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Tokyo, Japan. The current CEO is Naoki Okamura.
ALPMF has IPO date of 2010-04-26, 14,754 full-time employees, listed on the Other OTC, a market capitalization of $29.61B.
Astellas Pharma Inc. is a Japan-based pharmaceutical company founded in 1923 that manufactures, markets, and distributes medicines globally across oncology, urology, immunology, and infectious disease. The company's key products include XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, PADCEV for urothelial cancer, Myrbetriq for overactive bladder, Evrenzo for anemia in chronic kidney disease, and Prograf for transplant immunosuppression. Astellas maintains an extensive pipeline and strategic partnerships with leading institutions including Merck, Harvard University, and CytomX Therapeutics, as well as collaborations in emerging areas such as targeted radiotherapy, cell therapy, and epigenetic research. The company is headquartered in Tokyo and operates a diversified portfolio of prescription and specialty pharmaceutical products serving major markets worldwide.
